RT Journal Article
T1 PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis.
A1 Majem, Margarita
A1 Cobo, Manuel
A1 Isla, Dolores
A1 Marquez-Medina, Diego
A1 Rodriguez-Abreu, Delvys
A1 Casal-Rubio, Joaquín
A1 Bueno, Teresa Moran
A1 Bernabé-Caro, Reyes
A1 Parente, Diego Pérez
A1 Ruiz-Gracia, Pedro
A1 Arroyo, Marta Marina
A1 Paz-Ares, Luis
K1 PD-(L)1 inhibitors
K1 efficacy
K1 first-line treatment
K1 immunotherapy
K1 network meta-analysis
K1 non-small cell lung cancer
AB Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to evaluate the efficacy of first-line anti-PD-(L)1 monotherapy in advanced NSCLC patients with high PD-L1 expression (≥50%) compared to platinum-based chemotherapy. We also evaluated efficacy outcomes according to tumor mutational burden (TMB). To that end, we conducted a systematic review. Six clinical trials with 2111 patients were included. In head-to-head comparisons, immunotherapy showed a significant improvement in progression-free survival (PFS: HRpooled = 0.69, 95% CI: 0.52-0.90, p = 0.007), overall survival (OS: HRpooled = 0.69, 95% CI: 0.61-0.78; p
SN 2077-0383
YR 2021
FD 2021-03-26
LK http://hdl.handle.net/10668/17524
UL http://hdl.handle.net/10668/17524
LA en
DS RISalud
RD Apr 12, 2025